GNFT

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Wall Street analysts forecast GNFT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GNFT is 7.50 USD with a low forecast of 7.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Genfit SA revenue for the last quarter amounts to NaN USD, decreased % YoY.

Genfit SA. EPS for the last quarter amounts to USD, decreased % YoY.

Genfit SA (GNFT) has 180 emplpoyees as of December 15 2025.

Today GNFT has the market capitalization of 192.46M USD.